Skip to main content
OpenTrials
Completed

NCT Number: NCT01654172

Effect of Flavanol-rich Cocoa on Peripheral and Cerebral Blood Flow in Type 2 Diabetes

Cocoa flavanols form part of the family of chemicals (also found in red wine and tea) which have aroused interest due to population studies suggesting that diets high in these substances might reduce risks of heart disease. In the laboratory, these flavanols have been shown to cause blood vessels to widen and blood flow to increase. As dysfunction in this ability of blood vessels to widen is now thought to play a central role in the complications of diabetes, novel ways to mitigate this are constantly being sought.

The present study aims to use non-invasive magnetic resonance imaging (MRI) to measure foot and brain blood flow before and after 7 days consumption of a cocoa drink high in flavanols, in subjects with diabetes, with and without peripheral neuropathy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Nottingham

Nottingham, Notts, NG72UH, United Kingdom

About this study

Cocoa flavanols form part of the family of polyphenols (also found in red wine and tea) which have aroused interest due to epidemiological studies suggesting that diets high in these substances might reduce risks of heart disease. However, it is difficult to account for all sources of polyphenols in these epidemiological studies, and the level of cocoa product consumption was generally not well documented. Furthermore, in readily available cocoa products, processing may remove most of the flavanols, leading to such products varying considerably in flavanol content. Recently, laboratory studies of the effects of cocoa flavanols have suggested an effect on the relaxation of smooth muscle in blood vessel walls, specifically the element mediated by the endothelium (blood vessel wall). Studies using ultrasound methods in healthy volunteers have shown an increase in blood flow in the arm following temporary arterial occlusion.

As endothelial dysfunction is now thought to play a central role in the complications of diabetes, novel ways to mitigate this are constantly being sought. It is well recognised that diabetic peripheral nerve damage leads to abnormal foot blood flow, including impaired superficial skin blood flow, and that this is one of the factors delaying wound healing in diabetic foot ulcers (the single largest cost in secondary care diabetes).

Several techniques are currently used to monitor blood flow to the limbs, including venous occlusion plethysmography (VOP), laser Doppler methods and nuclear medicine techniques. These techniques have low spatial resolution, low specificity, are labour intensive, or require the use of injected radioactive contrast agents (which pose a particular risk to diabetic patients). Radiation dose also limits repeat studies.

The arterial spin labelling magnetic resonance (ASL MR) technique is non-invasive, but yields a quantifiable measure of blood flow with high resolution, and allows measurements to be repeated several times, as the technique uses no external contrast agents.

The present study aims to use non-invasive magnetic resonance imaging (MRI) to measure peripheral (foot) and brain blood flow at baseline and in response to a cocoa drink high in flavanols, in subjects with type 2 diabetes, with and without peripheral neuropathy.

Subjects will attend an initial screening visit. Measures of HbA1c, kidney function and blood pressure will be checked, along with ankle-brachial pressure index (to check for poor circulation), foot pulses, and examination for peripheral nerve damage and cardiac neuropathy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes
  • Peripheral neuropathy or free from neuropathy

Exclusion criteria

  • Current foot ulceration
  • Hypertension
  • Anti-hypertensive medications other than thiazide diuretics and ACE inhibitors
  • Ischaemic heart disease
  • Peripheral vascular disease (ABPI ,0.9 &/or impalpable foot pulses)
  • Chronic kidney disease
  • Poor glycaemic control
  • DVT
  • Epilepsy
  • Pregnancy
  • Contraindications to MRI
  • Intolerance to lactose or cow's milk protein

Treatment and study plan

High Flavanol Cocoa

Dietary Supplement

Total daily flavanol intake provided by the high flavanol drink is ~900mg

Low Flavanol Cocoa

Dietary Supplement

Primary outcomes

  1. Change in Fasting Brain Blood Flow

    Time frame: Day 0 and after 7d consumption of a cocoa drink

    Measured by ASL-MR at Day 0 and after 7d consumption of a cocoa drink to detect a change following intervention

Secondary outcomes

  1. Change in Brain blood flow after acute consumption of cocoa

    Time frame: 1,3,5 and 8hrs after cocoa consumption

    Measured at day 0, (before intervention commences)and after 7days consumption of a cocoa drink

  2. Change in Fasting foot blood flow

    Time frame: Day 0 and after 7d consumption of a cocoa drink

    Measured using ASL-MR

  3. Change in Foot blood flow after acute consumption of cocoa

    Time frame: 1,3,5 and 8hrs after cocoa consumption

    Measured at day 0, (before intervention commences)and after 7days consumption of a cocoa drink

  4. Change in Blood Flavanol concentration

    Time frame: Day 0 and after 7d consumption of a cocoa drink

    Measured at day 0, (before intervention commences)and after 7days consumption of a cocoa drink

  5. Change in Fasting oxidative stress status

    Time frame: Day 0 and after 7 days of consuming a cocoa drink

    Oxidative stress assessed by measuring concentration of homocysteine, CRP, 8-isoprostaglandin, arginine and nitric oxide metabolites in the blood.

  6. Change in diabetes control

    Time frame: Day 0 and after 7days of consuming a cocoa drink daily

    Assessment made from HbA1c, glucose and insulin concentration in the blood

Sponsors and collaborators

Lead sponsor

University of Nottingham

Other

Collaborators

  • Mars, Inc.

Registry information

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Jul 31, 2012
Registry last updated
Jul 31, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.